A randomised vaccine field trial in Kenya demonstrates protection against wildebeest-associated malignant catarrhal fever in cattle.

Wildebeest-associated malignant catarrhal fever (WA-MCF), a fatal disease of cattle caused by alcelaphine herpesvirus 1 (AlHV-1), is one of the most important seasonal diseases of cattle in wildebeest endemic areas, with annual incidence reaching 10%. Here we report efficacy of over 80% for a vaccine based on the attenuated AlHV-1 C500 strain, in preventing fatal WA-MCF in cattle exposed to natural wildebeest challenge. The study was conducted at Kapiti Plains Ranch Ltd, south-east of Nairobi, Kenya. In 2016, 146 cattle were selected for a randomised placebo-controlled trial. Cattle were stratified according to breed and age and randomly assigned to groups given vaccine or culture medium mixed with Emulsigen®. Cattle received prime and boost inoculations one month apart and few adverse reactions (n = 4) were observed. Indirect ELISA demonstrated that all cattle in the vaccine group developed a serological response to AlHV-1. The study herd was grazed with wildebeest from one month after booster vaccination. Three cattle, two that received vaccine and one control, succumbed to conditions unrelated to WA-MCF before the study ended. Twenty-five cattle succumbed to WA-MCF; four of the remaining 71 cattle in the vaccine group (5.6%) and 21 of the remaining 72 control cattle (29.2%; χ2 = 13.6, df = 1, p < 0.001). All of the WA-MCF affected cattle were confirmed by PCR to be infected with AlHV-1 and in 23 cases exhibited histopathology typical of WA-MCF. Vaccine efficacy was determined to be 80.6% (95% CI 46.5-93.0%). Hence, the AlHV-1 C500 vaccine is a safe and potentially effective novel method for controlling WA-MCF in cattle. The implementation of this vaccine may have significant impacts on marginalised cattle keeping communities.

Genetic characterization of ovine herpesvirus 2 strains involved in water buffaloes malignant catarrhal fever outbreaks in Southern Italy.

Ovine herpesvirus 2 (OvHV-2) was responsible for two outbreaks of malignant catarrhal fever (MCF) on two water buffalo farms in Southern Italy. In this study, the presence of this virus in the nasal swabs from sick animals as well as in the organs of dead buffaloes was ascertained by a Real-time PCR assay. Positive samples also underwent a relative quantitative analysis of the viral DNA in them. All the dead animals had the highest relative viral quantities, while buffaloes recovering from the virus had intermediate quantities, and asymptomatic OvHV-2-positive sheep had the lowest relative quantities (as compared with the calibrator). The strains involved in the MCF outbreaks underwent genetic characterization by sequencing segments of their ORF50, ORF75 and Ov9.5 genes. The results showed that the outbreaks were caused by two specific genetic variants of OvHV-2, and that these variants exhibit nucleotide differences at the loci analysed. Sheep living in the surrounding farms, as well as sheep kept with buffaloes, were also investigated as possible transmitters of the virus. In this regard, local strategies for the control of MCF should consider separating reservoir species from susceptible animals.

The efficacy of alcelaphine herpesvirus-1 (AlHV-1) immunization with the adjuvants Emulsigen® and the monomeric TLR5 ligand FliC in zebu cattle against AlHV-1 malignant catarrhal fever induced by experimental virus challenge.

Malignant catarrhal fever (MCF) is a fatal disease of cattle that, in East Africa, follows contact with wildebeest excreting alcelaphine herpesvirus 1 (AlHV-1). Recently an attenuated vaccine (atAlHV-1) was tested under experimental challenge on Friesian-Holstein (FH) cattle and gave a vaccine efficacy (VE) of approximately 90%. However testing under field conditions on an East African breed, the shorthorn zebu cross (SZC), gave a VE of 56% suggesting that FH and SZC cattle may respond differently to the vaccine. To investigate, a challenge trial was carried out using SZC. Additionally three adjuvant combinations were tested: (i) Emulsigen®, (ii) bacterial flagellin (FliC) and (iii) Emulsigen®+bacterial flagellin. We report 100% seroconversion in all immunized cattle. The group inoculated with atAlHV-1+Emulsigen® had significantly higher antibody titres than groups inoculated with FliC, the smallest number of animals that became infected and the fewest fatalities, suggesting this was the most effective combination. A larger study is required to more accurately determine the protective effect of this regime in SZC. There was an apparent inhibition of the antibody response in cattle inoculated with atAlHV-1+FliC, suggesting FliC might induce an immune suppressive mechanism. The VE in SZC (50-60%) was less than that in FH (80-90%). We speculate that this might be due to increased risk of disease in vaccinated SZC (suggesting that the vaccine may be less effective at stimulating an appropriate immune response in this breed) and/or increased survival in unvaccinated SZC (suggesting that these cattle may have a degree of prior immunity against infection with AlHV-1).

Wildebeest-associated malignant catarrhal fever: perspectives for integrated control of a lymphoproliferative disease of cattle in sub-Saharan Africa.

Wildebeest-associated malignant catarrhal fever (WA-MCF), an acute lymphoproliferative disease of cattle caused by alcelaphine herpesvirus 1 (AlHV-1), remains a significant constraint to cattle production in nomadic pastoralist systems in eastern and southern Africa. The transmission of WA-MCF is dependent on the presence of the wildlife reservoir, i.e. wildebeest, belonging to the species Connochaetes taurinus and Connochaetes gnou; hence, the distribution of WA-MCF is largely restricted to Kenya, Tanzania and the Republic of South Africa, where wildebeest are present. WA-MCF is analogous to sheep-associated MCF (SA-MCF) in many aspects, with the latter having sheep as its reservoir host and a more global distribution, mainly in developed countries with intensive livestock production systems. However, unlike SA-MCF, the geographic seclusion of WA-MCF may have contributed to an apparent neglect in research efforts aimed at increased biological understanding and control of the disease. This review aims to highlight the importance of WA-MCF and the need for intensified research towards measures for its integrated control. We discuss current knowledge on transmission and geographical distribution in eastern and southern Africa and the burden of WA-MCF in affected vulnerable pastoral communities in Africa. Recent findings towards vaccine development and pertinent knowledge gaps for future research efforts on WA-MCF are also considered. Finally, integrated control of WA-MCF based on a logical three-pronged framework is proposed, contextualizing vaccine development, next-generation diagnostics, and diversity studies targeted to the viral pathogen and cattle hosts.

A field vaccine trial in Tanzania demonstrates partial protection against malignant catarrhal fever in cattle.

Malignant catarrhal fever (MCF) is a fatal lymphoproliferative disease of cattle that, in East Africa, results from transmission of the causative virus, alcelaphine herpesvirus 1 (AlHV-1), from wildebeest. A vaccine field trial involving an attenuated AlHV-1 virus vaccine was performed over two wildebeest calving seasons on the Simanjiro Plain of northern Tanzania. Each of the two phases of the field trial consisted of groups of 50 vaccinated and unvaccinated cattle, which were subsequently exposed to AlHV-1 challenge by herding toward wildebeest. Vaccination resulted in the induction of virus-specific and virus-neutralizing antibodies. Some cattle in the unvaccinated groups also developed virus-specific antibody responses but only after the start of the challenge phase of the trial. PCR of DNA from blood samples detected AlHV-1 infection in both groups of cattle but the frequency of infection was significantly lower in the vaccinated groups. Some infected animals showed clinical signs suggestive of MCF but few animals went on to develop fatal MCF, with similar numbers in vaccinated and unvaccinated groups. This study demonstrated a baseline level of MCF-seropositivity among cattle in northern Tanzania of 1% and showed that AlHV-1 virus-neutralizing antibodies could be induced in Tanzanian zebu shorthorn cross cattle by our attenuated vaccine, a correlate of protection in previous experimental trials. The vaccine reduced infection rates by 56% in cattle exposed to wildebeest but protection from fatal MCF could not be determined due to the low number of fatal cases.

The economic impact of malignant catarrhal fever on pastoralist livelihoods.

This study is the first to partially quantify the potential economic benefits that a vaccine, effective at protecting cattle against malignant catarrhal fever (MCF), could accrue to pastoralists living in East Africa. The benefits would result from the removal of household resource and management costs that are traditionally incurred avoiding the disease. MCF, a fatal disease of cattle caused by a virus transmitted from wildebeest calves, has plagued Maasai communities in East Africa for generations. The threat of the disease forces the Maasai to move cattle to less productive grazing areas to avoid wildebeest during calving season when forage quality is critical. To assess the management and resource costs associated with moving, we used household survey data. To estimate the costs associated with changes in livestock body condition that result from being herded away from wildebeest calving grounds, we exploited an ongoing MCF vaccine field trial and we used a hedonic price regression, a statistical model that allows estimation of the marginal contribution of a good's attributes to its market price. We found that 90 percent of households move, on average, 82 percent of all cattle away from home to avoid MCF. In doing so, a herd's productive contributions to the household was reduced, with 64 percent of milk being unavailable for sale or consumption by the family members remaining at the boma (the children, women, and the elderly). In contrast cattle that remained on the wildebeest calving grounds during the calving season (and survived MCF) remained fully productive to the family and gained body condition compared to cattle that moved away. This gain was, however, short-lived. We estimated the market value of these condition gains and losses using hedonic regression. The value of a vaccine for MCF is the removal of the costs incurred in avoiding the disease.

Identification of immuno-reactive capsid proteins of malignant catarrhal fever viruses.

Malignant catarrhal fever (MCF) is a fatal disease of cattle and other ungulates caused by certain gamma-herpesviruses including alcelaphine herpesvirus-1 (AlHV-1) and ovine herpesvirus-2 (OvHV-2). An attenuated virus vaccine based on AlHV-1 has been shown to induce virus-neutralising antibodies in plasma and nasal secretions of protected cattle but the targets of virus-specific antibodies are unknown. Proteomic analysis and western blotting of virus extracts allowed the identification of eight candidate AlHV-1 virion antigens. Recombinant expression of selected candidates and their OvHV-2 orthologues confirmed that two polypeptides, the products of the ORF17.5 and ORF65 genes, were antigens recognised by antibodies from natural MCF cases or from AlHV-1 vaccinated cattle. These proteins have potential as diagnostic and/or vaccine antigens.

An immunisation strategy for the protection of cattle against alcelaphine herpesvirus-1-induced malignant catarrhal fever.

The aim of this study was to stimulate immunity in the oro-nasal-pharyngeal region of cattle to protect them from alcelaphine herpesvirus-1 (AlHV-1)-induced malignant catarrhal fever. Attenuated C500 strain AlHV-1 was used along with Freund's adjuvant intramuscularly (IM) in the upper neck region to immunise cattle. Virulent C500 strain AlHV-1 was used for intranasal challenge. Nine of ten cattle were protected. Protection was associated with high levels of neutralising antibody in nasal secretions. Some protected animals showed transient low levels of viral DNA in blood samples and in one lymph node sample after challenge whereas viral DNA was detected in the blood and in lymph node samples of all animals with MCF. This is the most promising immunisation strategy to date for the control of malignant catarrhal fever.

Sheep-associated malignant catarrhal fever virus: prospects for vaccine development.

Sheep-associated malignant catarrhal fever is emerging as a significant problem for several ruminant species worldwide. The inability to propagate the causative agent, ovine herpesvirus 2, in vitro has seriously hindered research efforts in the development of effective programs for control of the disease in clinically susceptible hosts. Recent molecular technologic advances have provided powerful tools for investigating this difficult-to-study virus. Identification of the infectious virus source, establishment of experimental animal models and completion of sequencing the genome for ovine herpesvirus 2 have put us in a position to pursue the development of vaccines for control of the disease. In this review, the authors briefly describe the current understanding of ovine herpesvirus 2 and prospectively discuss vaccine development against the virus.

Viral diseases of the ruminant nervous system.

This article presents the etiology, epidemiology, clinical features,and diagnosis of the primary viral neurologic diseases observed in ruminants. In general, these viral neurologic diseases are uncommon but often fatal. Rabies virus is perhaps the most important cause of encephalitis in cattle because of the public health implications. Other viral encephalitis diseases in ruminants include bovine herpesvirus encephalomyelitis, pseudorabies, malignant catarrhal fever, ovine and caprine lentiviral encephalitis, West Nile virus encephalitis, Borna disease, paramyxoviral sporadic bovine encephalomyelitis,and ovine encephalomyelitis (louping-ill).

Sheep-associated malignant catarrhal fever in a petting zoo.

In a privately owned petting zoo in Arizona, 17 deer from five different species, white-tailed deer (Odocoileus virginianus), Reeve's muntjac (Muntiacus reevesi), mule deer (Odocoileus hemionus), reindeer (Rangifer tarandus), and axis deer (Axis axis), died of suspected malignant catarrhal fever (MCF) over a period from late 1992 to early 1995. A PCR assay specific for ovine herpesvirus 2, the putative causative agent of sheep-associated MCF, and a competitive-inhibition enzyme-linked immunosorbent assay based on a monoclonal antibody specific to an epitope conserved among all known MCF viral isolates were used to investigate the outbreak. Ovine herpesvirus 2 DNA sequences were detected by PCR from fresh-frozen and/or formalin-fixed, paraffin-embedded tissue samples in seven deer out of eight available animals previously suspected as cases by histopathology. A high seroprevalence to the virus was found among mouflon (Ovis musimon, 80%) and pygmy goats (Capra hircus, 61%), both of which were present on the farm during the outbreak. Sixteen percent of fallow deer (Dama dama) were also seropositive to the virus. After removal of the mouflon and positive pygmy goats, no further MCF cases occurred on the farm, confirming the importance of careful management to avoid mixing clinically susceptible species with carrier species. Until better control measures are available, adherence to this practice is necessary if MCF is to be prevented in intense exposure environments such as zoos and densely populated animal parks.

Production of malignant catarrhal fever virus-free sheep.

The study was designed to better define the variables affecting the success of the establishment of ovine herpesvirus 2 (OHV-2)-free sheep flocks. A total of 38 lambs born to OHV-2-positive ewes was selected and divided into four groups. Three groups of 10 lambs each were separated from the positive ewes at 2, 2.5 and 3 months of age, respectively, and maintained in isolation facilities. One group of eight remained in the positive flock as controls. Peripheral blood samples from each lamb were examined regularly by PCR for OHV-2 DNA. All lambs (100%) that were weaned and maintained in isolation from the ages of 2, 2.5 and 3 months remained negative until the termination of the experiment at 1 year of age. One lamb was discovered to be PCR-positive on the day of isolation at 2.5 months of age, and was promptly removed from the isolation group. In contrast, all lambs (100%) that remained with the flock became PCR-positive by 6 months of age. The data confirmed that, with rare exceptions, separation of lambs from OHV-2 infected animals at around 2 months of age reliably yields OHV-2-free sheep. Appropriate PCR monitoring will enable the rare exceptions to be removed from the group, and is recommended as a safety measure.

Deer health and disease.

This paper describes the most significant diseases of farmed deer which have emerged over the last 30 or so years. It describes their characteristic signs, how control measures have evolved, their current status and gives an indication of future diagnostic and control measures. Overall, it shows that wild deer brought into a farming environment have developed some of the production limiting diseases which affect sheep and cattle, such as parasitism and trace element deficiencies. In addition, farmed deer are susceptible to potentially fatal diseases such as tuberculosis, malignant catarrhal fever and yersiniosis. A disease which has recently emerged and has the potential to be more serious than any of the above is Johne's disease. In North America, Chronic Wasting Disease occurs in captive and wild deer in only two states but has the potential to be a serious threat to wild and farmed deer elsewhere if it spreads. The zoonotic risks of diseases affecting deer are discussed, as well as stress, welfare and deer restraint. The productivity of farmed deer can be maximised by using a well-designed deer health programme integrated with good management and feeding.

Attempts to immunize cattle against virulent African malignant catarrhal fever virus (alcelaphine herpesvirus-1) with a herpesvirus isolated from American cattle.

Two consecutive weekly inoculations with a herpesvirus isolated from sick cattle in America (707K), protected four out of four steers against a first challenge with virulent African malignant catarrhal fever virus (alcelaphine herpesvirus-1), strain C500. Three of these steers were still protected in a rechallenge carried out 9.5 months after the first challenge. One inoculation with this agent did not protect such steers, and repeated weekly inoculations had the risk of inducing a malignant catarrhal fever-like disease. In addition such repeated inoculation did not necessarily confer adequate protection, either in the first or the second challenge. There was no correlation between the development of virus neutralizing antibody and protection to challenge with the virulent virus. Endonuclease analysis of the genome of 707K virus, revealed differences between the agent and the avirulent cell-free form of the virulent African malignant catarrhal fever virus (WC11).

Immunological relationships between malignant catarrhal fever virus (alcelaphine herpesvirus 1) and bovine cytomegalovirus (bovine herpesvirus 3).

Strains of malignant catarrhal fever virus (alcelaphine herpesvirus 1 (AHV-1)) and bovine cytomegalovirus (bovine herpesvirus 3 (BHV-3)) were compared for serological relatedness by cross-titration in an indirect immunofluorescent (IIF) antibody assay. There was definite cross-reactivity between these 2 viruses, with heterologous sera staining intracellular and membrane antigens of infected cells. Heterologous antibody titres were approximately 50-fold lower than homologous titres and could be removed by absorption with either homologous or heterologous virus-infected cells, but not with uninfected cells. Regression analyses of IIF antibody titres to AHV-1 and BHV-3 virus in 3 groups of wild ungulate sera also indicated a serological relationship between these herpesviruses. In a cross-immunity trial, 2 of 3 cattle immunized with a BHV-3 virus and 2 of 3 cattle immunized with avirulent AHV-1 resisted challenge with virulent AHV-1-infected blood which killed 3 unimmunized controls. These results are discussed particularly with respect to the involvement of BHV-3 in malignant catarrhal fever.

Role of wildebeest fetal membranes and fluids in the transmission of malignant catarrhal fever virus.

Malignant catarrhal fever virus was not isolated from samples of fetal membranes or fluid collected from 93 calving wildebeest (Connochaetes taurinus) in Kenya Maasailand. Cell-free strains of malignant catarrhal fever virus were very rapidly inactivated when exposed to the sun under field conditions, at least 3.0 log10 units/25 microliter being lost per hour at midday. It is suggested that wildebeest fetal membranes and fluids act as visual markers for areas of pasture which are particularly heavily contaminated with malignant catarrhal fever virus in oculonasal secretions of wildebeest calves. It is possible that starting to graze cattle one to two hours later each morning may be a useful measure for helping to protect cattle from malignant catarrhal fever in areas where they are forced to share pastures with calving wildebeest.

The protection of rabbits against the herpesvirus of malignant catarrhal fever by inactivated vaccines.

Cell-free virulent malignant catarrhal fever virus inactivated by either formalin or acetylethylenimine (AEI) and administered with Freund's complete adjuvant protected rabbits against two consecutive parenteral challenges with cell-free virus. However 'protected' rabbits succumbed within 20 days to later inoculation of infected rabbit lymph node suspensions. Both inactivated vaccines evoked high titres of neutralising and immunofluorescent antibody, but more of the rabbits given the AEI preparation showed pyrexia after the first challenge with cell-free virus. The degree of protection afforded was compared with that induced by inactivated antigens of other herpesviruses which cause lymphoproliferative disorders

Immunisation of cattle against the herpesvirus of malignant catarrhal fever: failure of inactivated culture vaccines with adjuvant.

Attempts were made to immunise cattle against the herpesvirus of malignant catarrhal fever by inoculating living or formalinised preparations of the agent, propagated in cell cultures and combined with Freund's incomplete adjuvant. High and persistent levels of virus-neutralising antibody were regularly demonstrable, especially following two intramuscular inoculations at an interval of six to eight weeks. In spite of this no protection was demonstrable against parenteral challenge with virulent virus, whether in cell-free or cell-associated form. In a controlled field trial vaccinated cattle showed no evidence of protection against natural challenge by exposure to wildebeest herds. It was concluded that humoral mechanisms are probably not important in determining resistance to infection with virulent MCFV.